Aquatic Capital Management LLC Alkermes Plc. Transaction History

Aquatic Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$23.21 - $27.24 $192,643 - $226,092	8,300 New	8,300 $200,000
Q3 2023 Nov 14, 2023	SELL	$27.17 - $31.97 $222,794 - $262,154	-8,200 Reduced 24.33%	25,500 $714,000
Q2 2023 Aug 14, 2023	BUY	$28.34 - $33.63 $955,058 - $1.13 Million	33,700 New	33,700 $1.06 Million
Q4 2022 Feb 14, 2023	SELL	$21.94 - $26.24 $28,522 - $34,112	-1,300 Reduced 4.05%	30,800 $804,000
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $706,200 - $1.02 Million	32,100 New	32,100 $717,000
Q2 2022 Aug 15, 2022	SELL	$26.4 - $30.54 $73,920 - $85,512	-2,800 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$23.07 - $27.99 $64,596 - $78,372	2,800 New	2,800 $74,000

361

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.55B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Aquatic Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aquatic Capital Management LLC with notifications on news.